Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance. Issue 5 (19th January 2020)

• Record Type: Journal Article
• Authors: Herrmann, Andreas B.; Müller, Martha‐Lena; Orth, Martin F.; Müller, Jörg P.; Zernecke, Alma; Hochhaus, Andreas; Ernst, Thomas; Butt, Elke; Frietsch, Jochen J.
• Is Part Of: Journal of cellular and molecular medicine. Volume 24:Issue 5(2020)
• Page Start: 2942
• Page End: 2955
• Publication Date: 2020-01-19
• Subjects: BCR‐ABL -- CML -- CXCR4 -- LASP1 -- nilotinib -- precursor cells; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.14910
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Chronic myeloid leukaemia (CML) is a clonal myeloproliferative stem cell disorder characterized by the constitutively active BCR‐ABL tyrosine kinase. The LIM and SH3 domain protein 1 (LASP1) has recently been identified as a novel BCR‐ABL substrate and is associated with proliferation, migration, tumorigenesis and chemoresistance in several cancers. Furthermore, LASP1 was shown to bind to the chemokine receptor 4 (CXCR4), thought to be involved in mechanisms of relapse. In order to identify potential LASP1‐mediated pathways and related factors that may help to further eradicate minimal residual disease (MRD), the effect of LASP1 on processes involved in progression and maintenance of CML was investigated. The present data indicate that not only overexpression of CXCR4, but also knockout of LASP1 contributes to proliferation, reduced apoptosis and migration as well as increased adhesive potential of K562 CML cells. Furthermore, LASP1 depletion in K562 CML cells leads to decreased cytokine release and reduced NK cell‐mediated cytotoxicity towards CML cells. Taken together, these results indicate that in CML, reduced levels of LASP1 alone and in combination with high CXCR4 expression may contribute to TKI resistance.